N/A N=17 Phenytoin and Multidose Activated Charcoal
Phenytoin Toxicity
Primary: Time of Elimination of Phenytoin in Patients With Elevated Phenytoin Levels — 41.1; 19.3 hours — p=0.049
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=17 Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes
Healthy
Primary: Difference in RAVLT Total T-Score Between Treatments — 57.76; 56.11; 53.08; 42.76 T-score — p=<0.01
Phase 4 N=20 Phenytoin and Driving Safety: A Randomized, Controlled Cross-Over Study
Cognitive Measures · Driving Simulator Performance
Primary: Number of Subjects Who Had a Driving Simulator Crash Event — 2; 0 Participants — p=0.50
Phase 2 N=71 Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
Optic Neuritis
Primary: Retinal Ganglion Cell Inner Plexiform Layer Thickness — 36.56; 34.65; 31; 29.42 micron
Phase 4 N=21 Phenytoin for Memory Impairment Secondary to Megestrol
Cognitive Impairment
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 51.89; 45.90; 48.37 T-scores — p=0.003
Phase 2 N=12 Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency
Tetrahydrobiopterin Deficiencies · Hyperphenylalaninemia, Non-Phenylketonuric
Primary: Blood Phenylalanine(Phe) Levels Measured at Specified Timepoints — 132.9; 72.2; 315.0; 104.1 μmol/L
Phase 1 N=32 Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 16350.6; 23806.5; 976.9; 954.3 ng/mL
N/A N=274 Pathogenesis of Adverse Drug Reactions
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Phase 3 N=90 Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet
Phenylketonurias
Primary: Amount of Dietary Supplemented Phenylalanine (Phe)Tolerated in Children With Phenylketonuria — 20.9; 2.9 mg/kg/day — p=<0.001
Phase 3 N=1,340 Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Partial Epilepsy
Primary: Summary of Treatment-Emergent Adverse Events (TEAEs) — 76; 35; 1104; 57 participants
Phase 3 N=111 Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006
Phenylketonuria
Primary: Tabulation of the Incidence and Frequency of All AEs and SAEs That Occur Throughout the Study. — 83.8; 33.3; 6.3; 0.9 percentage of subjects reporting events
Phase 4 N=21 Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
Acetaminophen Toxicity
Primary: Rise in Plasma Transaminases: Proportion of Responders. — 6; 8 Participants — p=0.59
Phase 3 N=89 Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels
Phenylketonurias
Primary: Change in Blood Phenylalanine Levels From Baseline to Week 6. — 843; 888; 607; 891 micromole per liter — p=<0.001
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
Phase 1 N=24 PP100-01 (Calmangafodipir) for Overdose of Paracetamol
Paracetamol Overdose
Primary: Safety Events — 6; 6; 6; 6 participants
Phase 4 N=13 Effect of Valproic Acid Concentration on Photic Response
Photosensitive Epilepsy
Primary: Difference in SPR During Placebo and VPA Infusions — 15.917; 14.609 standard photosensitive range (SPR) — p=0.016
Phase 1 N=26 A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia
Healthy
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 21380.0; 21370.0 ng*hr/mL
Phase 3 N=108 Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Epilepsy
Primary: Adverse Events — 126; 26 Number of adverse events
Phase 2 N=7 PF-06372865 in Subjects With Photosensitive Epilepsy
Reflex Epilepsy, Photosensitive
Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale
Phase 4 N=30 Concentrations of Amiodarone in Fat Tissue During Chronic Treatment
Arrhythmia · Atrial Fibrillation · Atrial Flutter
Primary: Relationship Between Amiodarone Concentration in Fat Tissue and Cumulated Dose. — 0.20 Correlation coefficient R
N/A N=14 Tolerability and Efficacy of Depakote-extended Release in the Elderly
Elderly · Epilepsy · Seizures
Primary: Effectiveness of Medication as Measured by Participation Through the End of the Trial. — 14 participants
N/A N=303 Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study
Neonatal Seizures
Primary: WIDEA Neurodevelopmental Outcome Score — 149.04; 162.46; 148.80; 151.89 score on a scale
Phase 4 N=158 IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
Tonic-clonic Seizure
Primary: Number of Participants Who Experienced a Recurrent Seizure After Treatment. — 2; 3 participants
Phase 3 N=47 Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Acute Lymphoblastic Leukemia (ALL)
Primary: Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity…
Phase 4 N=207 The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
Epilepsy
Primary: Retention Rate After 52 Weeks Maintenance Period — 104; 98 participants
N/A N=30 Pharmacokinetics of Acetaminophen in Pediatric Patients With Congenital Heart Disease
Congenital Heart Disease
Primary: Acetaminophen Serum Concentrations — 19; 17; 13; 13 mcg/mL
Phase 2 N=74 Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures
Nonconvulsive Seizures
Primary: Percentage of Subjects Who Experience no Nonconvulsive Seizures (NCS) for 24 Hours Following Treatment With LCM vs. fPHT, as Measured by Continuous…
Phase 3 N=46 Lamotrigine in Reducing Psychologic Side-Effect of Perioperative Ketamine
Reducing Psychological Side Effects of Ketamine
Primary: Psychologic Side-effects — 4; 4 score on a scale — p=0.08
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
Phase 3 N=319 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
Cancer
Primary: Neurotoxicity Assessment at Baseline — 8.5; 7.3; 5.23; 4.58 units on a scale